Theratechnologies Provides Update on Trogarzo™ (Ibalizumab-Uiyk) Injection Prescriptions and Reimbursement Status

World News: . []

MONTREAL, May 16, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX:TH) today disclosed, during its annual meeting, information on the number of scripts and reimbursement coverage for Trogarzo™ in the United States.

“We are quite pleased with the reaction from patients, physicians and payers since we announced the commercial availability of Trogarzo™ on April 30, 2018,” said Luc Tanguay, President and Chief Executive Officer, Theratechnologies Inc. “It did not take long to observe strong interest from HIV clinics and to obtain reimbursement from public and private payers,” added Mr. Tanguay.

“Major private insurers such as Cigna, Aetna, United Healthcare and Kaiser Permanente have already amended their reimbursement policy to include Trogarzo™. As we stand, about 25% of privately insured lives in the U.S. now have access to Trogarzo™. In addition, Medicare has quickly made it possible to approve individual requests. Medicaid coverage has been secured in California and Florida, among others, which, together, represent close to 20% of patients covered under Medicaid state plans. All this happened just two months after approval,” said Mr. Tanguay.

“While symbolic, we will reach the 100 prescription milestone within three weeks of commercial availability, which is reason to be optimistic about the demand for Trogarzo™,” added Mr. Tanguay.

“Our entire team continues to work very hard to quickly bring this unique product to patients faced with the challenge of multidrug resistant HIV,” concluded Mr. Tanguay.

Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Theratechnologies’ control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. These assumptions include but are not limited to, the following: the number of prescriptions for Trogarzo will continue to increase over time and the level of reimbursement by public and private payers will also continue to grow. These risks and uncertainties include, but are not limited to, the risk that the number of patients suffering from multidrug resistant HIV-1 is less than anticipated, thereby decreasing the number of prescriptions for Trogarzo, the risk that physicians do not value Trogarzo as a treatment for HIV-patients faced with multidrug resistance, the risk that private and/or public payers do not reimburse Trogarzo or impose restrictions as a condition to reimbursing Trogarzo, all of which could lead to a restriction on the availability of Trogarzo for patients.

We refer potential investors to the “Risk Factors” section of our Annual Information Form (AIF) dated February 6, 2018 for additional risks and uncertainties about Theratechnologies. The AIF is available on the Company’s website at and on SEDAR at The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward-looking statements. Forward-looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise, except as may be required by applicable law.

More news and information about Theratechnologies

Published By:

Globe Newswire: 16:30 GMT Wednesday 16th May 2018

Published: .

Search for other references to "theratechnologies" on SPi News

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
Sector Publishing Intelligence Ltd.
Ground Floor Offices, Little Keep Gate, Barrack Road, Dorchester, Dorset DT1 1AH
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us

Advertising on SPi News: Information For Advertisers